To the full analysis
Paysign stock: growth
PAYSPaysign reported $82.03M in revenue for fiscal 2025, up 40.5% on the prior year, up 27.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
21.8%
per year from 2010 to 2025, per share 18.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
56.6%
per year from 2010 to 2025, per share 52%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2010 | |
|---|---|---|---|
| Revenue | 27.7% | 26.0% | 21.8% |
| Revenue per share | 25.2% | 22.1% | 18.2% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 37.5% | no data | 56.6% |
| Free cash flow per share | 34.8% | no data | 52.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $4.28M | −$8.29K | $61.34K |
| 2011 | $3.24M | $215.29K | $26.61K |
| 2012 | $6.7M | $1.82M | $1.82M |
| 2013 | $6.31M | $611.68K | −$859.05K |
| 2014 | $10.29M | $2.61M | $2.55M |
| 2015 | $8.11M | −$2.41M | −$1.65M |
| 2016 | $10.42M | $1.4M | $379.71K |
| 2017 | $15.23M | $1.79M | $5.63M |
| 2018 | $23.42M | $2.59M | $14.4M |
| 2019 | $34.67M | $7.45M | $9.49M |
| 2020 | $24.12M | −$9.14M | $10.43M |
| 2021 | $29.46M | −$2.72M | $12.55M |
| 2022 | $38.03M | $1.03M | $21.23M |
| 2023 | $47.27M | $6.46M | $20.57M |
| 2024 | $58.38M | $3.82M | $13.46M |
| 2025 | $82.03M | $7.55M | $51.24M |
Revenue by segment
How Paysign, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Plasma Industry56%
- Pharma Industry41%
- Other3%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Plasma Industry | $43.88M | $45.62M | 55.6% |
| Pharma Industry | $12.65M | $33.89M | 41.3% |
| Other | $1.85M | $2.52M | 3.1% |
| Total revenue | $58.38M | $82.03M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 17 Apr 2026)
- Valuation signal Fairly valued since 11 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.